(Q39699224)

14 September 2017

title

Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer (English)

1 reference

14 September 2017

0 references

Guang Chen

1

1 reference

14 September 2017

Na Yang

2

1 reference

14 September 2017

Xiang Wang

3

1 reference

14 September 2017

Si-Yuan Zheng

4

1 reference

14 September 2017

Yi Chen

5

1 reference

14 September 2017

Lin-Jiang Tong

6

1 reference

14 September 2017

Yi-Xue Li

7

1 reference

14 September 2017

Ling-Hua Meng

8

1 reference

14 September 2017

Jian Ding

9

1 reference

14 September 2017

publication date

28 May 2010

1 reference

Journal of Molecular Medicine

14 September 2017

published in

1 reference

14 September 2017

volume

88

1 reference

14 September 2017

issue

9

1 reference

14 September 2017

page(s)

941-952

1 reference

Rapamycin resistance tied to defective regulation of p27Kip1.

14 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-010-0635-0

Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-010-0635-0

Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX.

21 January 2018

1 reference

12 December 2020

Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer

1 reference

12 December 2020

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

12 December 2020

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

12 December 2020

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel

1 reference

12 December 2020

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

12 December 2020

Regulation and cellular roles of phosphoinositide 5-kinases

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

12 December 2020

Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis

1 reference

12 December 2020

Molecular mechanisms of mTOR-mediated translational control

1 reference

12 December 2020

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

1 reference

12 December 2020

The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies

1 reference

12 December 2020

1 reference

12 December 2020

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

12 December 2020

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

1 reference

12 December 2020

mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation

1 reference

12 December 2020

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

12 December 2020

Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients

1 reference

12 December 2020

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

1 reference

12 December 2020

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

12 December 2020

Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy.

1 reference

12 December 2020

Defining the role of mTOR in cancer

1 reference

12 December 2020

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

1 reference

12 December 2020

Molecular analysis of the p27/kip1 gene in breast cancer.

1 reference

12 December 2020

p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells

1 reference

12 December 2020

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

12 December 2020

p27 modulates cell cycle progression and chemosensitivity in human malignant glioma.

1 reference

12 December 2020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

12 December 2020

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

1 reference

12 December 2020

10.1007/S00109-010-0635-0

Identifiers

DOI

1 reference

14 September 2017

1 reference